Lee Ahran, Yoo Jung Sik, Yoon Eun-Jeong
Division of Antimicrobial Resistance Research, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Republic of Korea.
Antibiotics (Basel). 2024 Oct 20;13(10):995. doi: 10.3390/antibiotics13100995.
is a major causative pathogen for antibiotic-associated diarrhea and infections (CDIs) may lead to life-threatening diseases in clinical settings. Most of the risk factors for the incidence of CDIs, i.e., antibiotic use, treatment by proton pump inhibitors, old age, and hospitalization, are associated with dysbiosis of gut microbiota and associated metabolites and, consequently, treatment options for CDIs include normalizing the composition of the intestinal microbiome. In this review, with an introduction to the CDI and its global epidemiology, CDI-associated traits of the gut microbiome and its metabolites were reviewed, and microbiome-targeting treatment options were introduced, which was approved recently as a new drug by the United States Food and Drug Administration (U.S. FDA), rather than a medical practice.
是抗生素相关性腹泻的主要致病病原体，艰难梭菌感染（CDIs）在临床环境中可能导致危及生命的疾病。CDIs发生的大多数风险因素，即抗生素使用、质子泵抑制剂治疗、老年和住院，都与肠道微生物群及其相关代谢物的生态失调有关，因此，CDIs的治疗选择包括使肠道微生物组的组成正常化。在这篇综述中，在介绍CDI及其全球流行病学的基础上，回顾了肠道微生物组及其代谢物与CDI相关的特征，并介绍了针对微生物组的治疗选择，这是最近被美国食品药品监督管理局（美国FDA）批准为新药的，而不是一种医疗实践。
